Nicolas Vuilleumier
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022; 13:1016927.
Oct 13, 2022Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Oct 13, 2022Front Immunol 2022; 13:1016927
Raptis Catherine E, Berger Christoph T, Ciurea Adrian, Andrey Diego O, Polysopoulos Christos, Lescuyer Pierre, Maletic Tanja, Riek Myriam, Scherer Almut, von Loga Isabell, Safford Judith, Lauper Kim, Möller Burkhard, Vuilleumier Nicolas, Finckh Axel, Rubbert-Roth Andrea
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmueller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkola A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open 2022; 8
Jan 1, 2022Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Jan 1, 2022RMD Open 2022; 8
Schmiedeberg Kristin, Abela Irene A, Pikor Natalia, Vuilleumier Nicolas, Schwarzmueller Magdalena, Epp Selina, Pagano Sabrina, Grabherr Sarah, Patterson Angelica Brooke, Nussberger Madalina, Trkola Alexandra, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Rottländer Y, Pirker I, von Kempis J (2022). Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study.
Dec 28, 2021Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Dec 28, 2021ACR Converence 2021
Rubbert-Roth Andrea, Vuilleumier Nicolas, Ludewig Burkhard, Schmiedeberg Kristin, Rottländer Yella, Pirker Ian, von Kempis Johannes
Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
Vuilleumier N, Pagano S, Ludewig B, Schmiedeberg K, Haller C, von Kempis J, Rubbert-Roth A. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?. Eur J Clin Invest 2021; 52:e13713.
Nov 29, 2021Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
Nov 29, 2021Eur J Clin Invest 2021; 52:e13713
Vuilleumier Nicolas, Pagano Sabrina, Ludewig Burkhard, Schmiedeberg Kristin, Haller Christoph, von Kempis Johannes, Rubbert-Roth Andrea
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatol 2021; 4:e11-e13.
Oct 26, 2021Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Oct 26, 2021Lancet Rheumatol 2021; 4:e11-e13
Schmiedeberg Kristin, Vuilleumier Nicolas, Pagano Sabrina, Albrich Werner, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Haller C, von Kempis J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Lancet Rheumatol 2021; 3:e470-e472.
Jun 8, 2021Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
Jun 8, 2021Lancet Rheumatol 2021; 3:e470-e472
Rubbert-Roth Andrea, Vuilleumier Nicolas, Ludewig Burkhard, Schmiedeberg Kristin, Haller Christoph, von Kempis Johannes